AiCuris Anti-infective Cures AG
AiCuris is a clinical stage pharmaceutical company focused on research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. AiCuris’s fully stacked research and development engine has a proven track record with one marketed drug and a pipeline of anti-infectives in clinical development.
As innovator in the field of anti-infective therapies, AiCuris targets solving medical needs of today and prepares for future health threats including viral pandemics and antimicrobial resistance combining the experience of big pharma and the flexibility of a small biotech. Aicuris is driven by scientific excellence and collaborates with a wide array of academic and business partners, providing access to technologies, platforms and novel approaches.
AiCuris at a glance:
| Field of Activity | Anti-infectives incl. antivirals (HCMV, HSV, Hepatitis B virus, Adenovirus, SARS-CoV-2 and other viruses with pandemic potential) and antibacterials (incl. fighting AMR). Pandemic & Resistance Emergency Preparedness – PREP Program |
| Ownership Structure and Financing | Private investors, led by the family office of the Dres. Strüngmann. |
| Partners | Merck & Co. (MSD): Licensee of Letermovir, Lysando, Max-Planck-Institute, ICIQ and others. AiCuris intends to move its projects at least to a clinical PoC before starting licensing/partnering activities. Active in-licensing strategy for pre-clinical and early clinical projects.AiCubator – a corporate incubator for early anti-infective projects with next round of submission starting in October 2022. |
| Products/Services | Selected AiCuris’ Programs:
Letermovir (licensed to MSD): HCMV, marketed (HSCT), Ph 3 (SOT) Pritelivir: Resistant HSV, Ph 3 AIC649: HBV, SARS-CoV-2 (pandemic preparedness), Ph 1 (in patients) AIC468: BVK Nephropathy Artilysine: Several approaches in the field of bacteriology |
| Unique Selling Point | AiCuris possesses a fully stacked research and development engine generating highly innovate anti-infective therapies acting via new mechanisms of actions. |
| Membership in networks / associations | EFPIA, BEAM Alliance, BIO Deutschland, BioRiver, BAND |
| Date of Incorporation/ Number of Employees |
2006/80 |
Contact :
| Address | Friedrich-Ebert-Str. 475 / Building 302 42117 Wuppertal |
| Telephone/Telefax | +49 202 317 63 -0/-1177 |
| info@aicuris.com | |
| Web Address | www.aicuris.com |
| Social Media | LinkedIn Twitter |
- AiCuris ernennt Dr. Sabrina Kuttruff-Coqui zum Finanzvorstand
- AiCuris erhält NRW-Förderung über 5,9 Mio. EUR
- AiCuris wird zur AG, um „zukünftiges Wachstum“ zu ermöglichen – folgt das IPO?
- AiCuris-Team für den Deutschen Zukunftspreis 2018 nominiert
- Nach FDA-Zulassung: AiCuris-Wirkstoff kommt nach Europa
- AiCuris' Lizenznehmer MSD erhält FDA-Zulassung für PREVYMIS (Letermovir)
- „Die Preisvorstellung von Antibiotika muss und wird sich ändern“
- AiCuris erhält Fast-Track-Status der FDA
- Dem Horror entgegen wirken